甲状腺相关性眼病的发病机制进展与新药研发
Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development.
作者信息
Huang Yazhuo, Fang Sijie, Zhang Shuo, Zhou Huifang
机构信息
Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.
出版信息
Taiwan J Ophthalmol. 2020 Jul 17;10(3):174-180. doi: 10.4103/tjo.tjo_18_20. eCollection 2020 Jul-Sep.
Abstract
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still unclear. In recent years, great progress has been made in revealing the mechanism of TAO. Various biological and immunosuppressive agents have emerged in an endless stream, showing encouraging results. Strengthening the basic research, establishing ideal animal models, deeply understanding the pathogenesis, and developing novel targeted drugs are of great significance to guide the clinical diagnosis and management of TAO and improve the prognosis of patients.
摘要
甲状腺相关眼病（TAO）是毒性弥漫性甲状腺肿（格雷夫斯病）最常见的甲状腺外表现，也称为格雷夫斯眼病/眼眶病。作为一种器官特异性自身免疫性疾病，TAO的发病机制仍不清楚。近年来，在揭示TAO的发病机制方面取得了很大进展。各种生物制剂和免疫抑制剂层出不穷，显示出令人鼓舞的效果。加强基础研究，建立理想的动物模型，深入了解发病机制，开发新型靶向药物，对指导TAO的临床诊断和治疗以及改善患者预后具有重要意义。
相似文献
1
Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development.甲状腺相关性眼病的发病机制进展与新药研发
Taiwan J Ophthalmol. 2020 Jul 17;10(3):174-180. doi: 10.4103/tjo.tjo_18_20. eCollection 2020 Jul-Sep.
2
Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.新型甲状腺与眼肌共享蛋白G2s的克隆与特性分析：针对G2s的自身抗体与格雷夫斯甲状腺功能亢进症患者的眼病密切相关。
J Clin Endocrinol Metab. 2000 Apr;85(4):1641-7. doi: 10.1210/jcem.85.4.6553.
3
Decreased Expression of TIM-3 on Th17 Cells Associated with Ophthalmopathy in Patients with Graves' Disease.Th17 细胞上 TIM-3 表达降低与 Graves 病患者眼病相关。
Curr Mol Med. 2018;18(2):83-90. doi: 10.2174/1566524018666180705105753.
4
Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.细胞因子在甲状腺相关性眼病中既是“反派”，又是潜在的治疗靶点：从实验室到临床应用
Expert Rev Ophthalmol. 2014 Jun;9(3):227-234. doi: 10.1586/17469899.2014.917960.
5
Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.新疗法在格雷夫斯病和甲状腺相关性眼病中的应用：动物模型及向人类临床试验的转化
Thyroid. 2008 Sep;18(9):973-81. doi: 10.1089/thy.2007.0406.
6
Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction.甲状腺相关性眼病及相关疾病中针对眼眶靶细胞的抗体依赖性细胞介导的细胞毒性；血清细胞毒性抗体与眼肌功能障碍参数之间的密切关系。
J Endocrinol Invest. 1996 Jun;19(6):334-41. doi: 10.1007/BF03344966.
7
Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.使用抗甲状腺药物或碘-131治疗格雷夫斯甲亢后出现的甲状腺相关眼病。
J Clin Endocrinol Metab. 2009 Oct;94(10):3700-7. doi: 10.1210/jc.2009-0747. Epub 2009 Sep 1.
8
Reevaluation of the prevalences of serum autoantibodies reactive with "64-kd eye muscle proteins" in patients with thyroid-associated ophthalmopathy.对甲状腺相关性眼病患者中与“64-kd眼肌蛋白”反应的血清自身抗体患病率的重新评估。
Thyroid. 1998 Feb;8(2):175-9. doi: 10.1089/thy.1998.8.175.
9
Epidemiology and Clinical Features of Thyroid-associated Orbitopathy in Accra.阿克拉甲状腺相关性眼眶病的流行病学及临床特征
Middle East Afr J Ophthalmol. 2017 Oct-Dec;24(4):183-189. doi: 10.4103/meajo.MEAJO_91_17.
10
Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy.眼肌抗体与甲状腺相关性眼病的亚型
Thyroid. 2002 Mar;12(3):187-91. doi: 10.1089/105072502753600115.
引用本文的文献
1
The outcomes of endoscopic orbital decompression combined with fat decompression for thyroid-associated ophthalmopathy.内镜眼眶减压术联合脂肪减压术治疗甲状腺相关眼病的疗效。
BMC Ophthalmol. 2023 May 16;23(1):217. doi: 10.1186/s12886-023-02957-7.
2
Recent progress in N6-methyladenosine modification in ocular surface diseases.眼表疾病中N6-甲基腺嘌呤修饰的最新进展
Int J Ophthalmol. 2023 Apr 18;16(4):645-651. doi: 10.18240/ijo.2023.04.20. eCollection 2023.
3
Traditional Chinese medicine in thyroid-associated orbitopathy.传统中医药在甲状腺相关眼病中的应用。
J Endocrinol Invest. 2023 Jun;46(6):1103-1113. doi: 10.1007/s40618-023-02024-4. Epub 2023 Feb 12.
4
miR-96-5p Induces Orbital Fibroblasts Differentiation by Targeting Smad7 and Promotes the Development of Thyroid-Associated Ophthalmopathy.miR-96-5p通过靶向Smad7诱导眼眶成纤维细胞分化并促进甲状腺相关性眼病的发展。
Evid Based Complement Alternat Med. 2022 Feb 27;2022:8550307. doi: 10.1155/2022/8550307. eCollection 2022.
5
MiR-143 Targets IGF-1R to Suppress Autoimmunity in Thyroid-Associated Ophthalmopathy.微小RNA-143靶向胰岛素样生长因子-1受体以抑制甲状腺相关性眼病中的自身免疫反应。
J Inflamm Res. 2022 Mar 1;15:1543-1554. doi: 10.2147/JIR.S339483. eCollection 2022.
6
Ocular Complications of Obstructive Sleep Apnea.阻塞性睡眠呼吸暂停的眼部并发症
J Clin Med. 2021 Jul 31;10(15):3422. doi: 10.3390/jcm10153422.
7
Mechanisms That Underly T Cell Immunity in Graves' Orbitopathy.甲状腺眼病中 T 细胞免疫的作用机制。
Front Endocrinol (Lausanne). 2021 Apr 1;12:648732. doi: 10.3389/fendo.2021.648732. eCollection 2021.
本文引用的文献
1
Teprotumumab for the Treatment of Active Thyroid Eye Disease.特罗特鲁单抗治疗活动性甲状腺眼病。
N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.
2
World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.第七届世界口腔医学研讨会：干燥综合征唾液腺疾病的免疫生物学：系统评价。
Oral Dis. 2019 Jun;25 Suppl 1(Suppl 1):102-110. doi: 10.1111/odi.13062.
3
Defective Regulatory B Cells Are Associated With Thyroid-Associated Ophthalmopathy.缺陷调节性B细胞与甲状腺相关性眼病有关。
J Clin Endocrinol Metab. 2019 Sep 1;104(9):4067-4077. doi: 10.1210/jc.2018-01812.
4
The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy.T 细胞发病机制在甲状腺相关性眼病中的作用。
Eye (Lond). 2019 Feb;33(2):176-182. doi: 10.1038/s41433-018-0279-9. Epub 2018 Dec 7.
5
Insights Into Local Orbital Immunity: Evidence for the Involvement of the Th17 Cell Pathway in Thyroid-Associated Ophthalmopathy.局部眼眶免疫的新认识：Th17 细胞通路在甲状腺相关性眼病中的作用。
J Clin Endocrinol Metab. 2019 May 1;104(5):1697-1711. doi: 10.1210/jc.2018-01626.
6
Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy.CD34+ 纤维细胞伪装成眼眶成纤维细胞在甲状腺相关眼病中的潜在作用。
J Clin Endocrinol Metab. 2019 Feb 1;104(2):581-594. doi: 10.1210/jc.2018-01493.
7
Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.托珠单抗治疗中重度糖皮质激素抵抗性格雷夫斯眼病患者的疗效：一项随机临床试验。
Am J Ophthalmol. 2018 Nov;195:181-190. doi: 10.1016/j.ajo.2018.07.038. Epub 2018 Aug 4.
8
New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.自身免疫性重症肌无力的新途径和治疗靶点。
J Neuromuscul Dis. 2018;5(3):265-277. doi: 10.3233/JND-170294.
9
Decreased Expression of TIM-3 on Th17 Cells Associated with Ophthalmopathy in Patients with Graves' Disease.Th17 细胞上 TIM-3 表达降低与 Graves 病患者眼病相关。
Curr Mol Med. 2018;18(2):83-90. doi: 10.2174/1566524018666180705105753.
10
CD34- Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF-α Expression in CD34+ Fibroblasts and Fibrocytes.甲状腺相关眼病患者眶成纤维细胞调节 CD34+成纤维细胞和纤维细胞中 TNF-α 的表达。
Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2615-2622. doi: 10.1167/iovs.18-23951.
Zotero 插件